Literature DB >> 15811252

Coronary heart disease and polymorphisms in genes affecting lipid metabolism and inflammation.

François Cambien1.   

Abstract

Several biologic systems contribute to the pathophysiology of atherosclerosis and its complications, and within each of these systems many genes have been explored to establish the possible implication of their variability in coronary heart disease (CHD) risk. This report is focused on recent results pertaining to lipid and inflammatory genes, their variability, and their relationship with intermediate phenotypes and CHD. For both systems, there is no evidence at the present time that testing genetic polymorphisms might be of any benefit to the patient, for the diagnosis or prognosis of CHD, or for tailoring drug prescription. Understanding the genetics of complex traits like CHD will require a system approach that allows a modeling of the interaction among genes as well as between genetic and nongenetic sources of variation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15811252     DOI: 10.1007/s11883-005-0005-5

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  78 in total

1.  Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis.

Authors:  D H McDermott; J P Halcox; W H Schenke; M A Waclawiw; M N Merrell; N Epstein; A A Quyyumi; P M Murphy
Journal:  Circ Res       Date:  2001-08-31       Impact factor: 17.367

2.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

3.  In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction.

Authors:  David-Alexandre Tregouet; Sylvain Ricard; Viviane Nicaud; Isabelle Arnould; Stéphane Soubigou; Marie Rosier; Nicolas Duverger; Odette Poirier; Sandrine Macé; Frank Kee; Caroline Morrison; Patrice Denèfle; Laurence Tiret; Alun Evans; Jean-Francois Deleuze; Francois Cambien
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-02-12       Impact factor: 8.311

4.  Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS).

Authors:  Federica Basso; Gordon D O Lowe; Ann Rumley; Alex D McMahon; Steve E Humphries
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

5.  Nucleotide variation, haplotype structure, and association with end-stage renal disease of the human interleukin-1 gene cluster.

Authors:  Jeannette T Bensen; Carl D Langefeld; Gregory A Hawkins; Linda E Green; Josyf C Mychaleckyj; Catherine S Brewer; Deborah S Kiger; Scott M Binford; Carla J Colicigno; Dax C Allred; Barry I Freedman; Donald W Bowden
Journal:  Genomics       Date:  2003-08       Impact factor: 5.736

6.  Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.

Authors:  S Matthijs Boekholdt; Jan-Albert Kuivenhoven; Nicholas J Wareham; Ron J G Peters; J Wouter Jukema; Robert Luben; Sheila A Bingham; Nicholas E Day; John J P Kastelein; Kay-Tee Khaw
Journal:  Circulation       Date:  2004-08-30       Impact factor: 29.690

7.  Cholesteryl ester transfer protein promoter single-nucleotide polymorphisms in Sp1-binding sites affect transcription and are associated with high-density lipoprotein cholesterol.

Authors:  J F Thompson; D B Lloyd; M E Lira; P M Milos
Journal:  Clin Genet       Date:  2004-09       Impact factor: 4.438

8.  No association of interleukin-6 gene polymorphism (-174 G/C) with myocardial infarction or traditional cardiovascular risk factors.

Authors:  Wolfgang Lieb; Robert Pavlik; Jeanette Erdmann; Bjoern Mayer; Stephan R Holmer; Marcus Fischer; Andrea Baessler; Christian Hengstenberg; Hannelore Loewel; Angela Doering; Guenter A Riegger; Heribert Schunkert
Journal:  Int J Cardiol       Date:  2004-11       Impact factor: 4.164

9.  Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines.

Authors:  Jean Louis Georges; Hans J Rupprecht; Stefan Blankenberg; Odette Poirier; Christoph Bickel; Gerd Hafner; Viviane Nicaud; Jürgen Meyer; François Cambien; Laurence Tiret
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

10.  The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy.

Authors:  Greetje J de Grooth; Kim E Zerba; Shu-Pang Huang; Zenta Tsuchihashi; Todd Kirchgessner; René Belder; Priya Vishnupad; Beihong Hu; Anke H E M Klerkx; Aeilko H Zwinderman; J Wouter Jukema; Frank M Sacks; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094

View more
  7 in total

1.  APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study.

Authors:  Dolores Corella; Chao-Qiang Lai; Serkalem Demissie; L Adrienne Cupples; Alisa K Manning; Katherine L Tucker; Jose M Ordovas
Journal:  J Mol Med (Berl)       Date:  2007-01-09       Impact factor: 4.599

2.  The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction.

Authors:  P González; M García-Castro; J R Reguero; A Batalla; A G Ordóñez; R L Palop; I Lozano; M Montes; V Alvarez; E Coto
Journal:  J Med Genet       Date:  2005-06-15       Impact factor: 6.318

Review 3.  Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.

Authors:  Kristin L White; David N Rider; Kimberly R Kalli; Keith L Knutson; Gail P Jarvik; Ellen L Goode
Journal:  Cancer Causes Control       Date:  2011-02-27       Impact factor: 2.506

Review 4.  Genetics of macrovascular complications in diabetes.

Authors:  Frédéric Fumeron; André F Reis; Gilberto Velho
Journal:  Curr Diab Rep       Date:  2006-04       Impact factor: 4.810

5.  Polymorphisms in 33 inflammatory genes and risk of myocardial infarction--a system genetics approach.

Authors:  Sandrine Barbaux; David-Alexandre Tregouet; Viviane Nicaud; Odette Poirier; Claire Perret; Tiphaine Godefroy; Carole Francomme; Christophe Combadiere; Dominique Arveiler; Gerald Luc; Jean-Bernard Ruidavets; Alun E Evans; Frank Kee; Caroline Morrison; Laurence Tiret; Stefan Martin Brand-Herrmann; François Cambien
Journal:  J Mol Med (Berl)       Date:  2007-07-19       Impact factor: 4.599

6.  Apolipoprotein Gene Polymorphisms (APOB, APOC111, APOE) in the Development of Coronary Heart Disease in Ethnic Groups of Kazakhstan.

Authors:  S Berkinbayev; M Rysuly; A Mussayev; K Blum; N Baitasova; A Mussagaliyeva; G Dzhunusbekova; B Makhatov; Aa Mussayev; A Yeshmanova; R Lesbekova; Y Marchuk; R Azhibekova; M Oscar-Berman; M Kulmaganbetov
Journal:  J Genet Syndr Gene Ther       Date:  2014-01-24

7.  Association of BAX hypermethylation with coronary heart disease is specific to individuals aged over 70.

Authors:  Limei Zhang; Huihui Ji; Yi Huang; Haochang Hu; Bin Li; Yong Yang; Hang Yu; Xiaoying Chen; Wenxia Li; Fang Liu; Shi Wang; Chunming Wang; Ke Chen; Yingchun Bao; Haibo Liu; Shiwei Duan
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.